Pharmacological Profile of Difamilast, a Novel Selective Phosphodiesterase 4 Inhibitor, for Topical Treatment of Atopic Dermatitis
Author:
Publisher
American Society for Pharmacology & Experimental Therapeutics (ASPET)
Subject
Pharmacology,Molecular Medicine
Reference40 articles.
1. Phosphodiesterase-4 Inhibitor Therapy for Lung Diseases
2. Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use
3. Topical Calcineurin Inhibitors for Atopic Dermatitis: Review and Treatment Recommendations
4. A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast;Chiricozzi;Expert Rev Clin Immunol,2016
5. Biochemistry and Physiology of Cyclic Nucleotide Phosphodiesterases: Essential Components in Cyclic Nucleotide Signaling
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Synthetic approaches and clinical application of representative small-molecule inhibitors of phosphodiesterase;European Journal of Medicinal Chemistry;2024-11
2. Phosphodiesterase-4-Inhibitoren in der Dermatologie;Die Dermatologie;2024-08-30
3. An Interim Report of a Phase 3, Long-Term, Open-Label Study to Evaluate Efficacy and Safety of Difamilast Ointment in Japanese Infants with Atopic Dermatitis;Dermatology and Therapy;2024-07-29
4. PDE4D: A Multipurpose Pharmacological Target;International Journal of Molecular Sciences;2024-07-24
5. The use of essential oils in atopic dermatitis: a review;Current Medical Research and Opinion;2024-04-25
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3